Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997–2007

Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects... ABSTRACT Purpose To investigate associations between maternal use of common medications and herbals during early pregnancy and risk for hypospadias in male infants. Methods We used data from the National Birth Defects Prevention Study, a multi‐site, population‐based, case–control study. We analyzed data from 1537 infants with second‐degree or third‐degree isolated hypospadias and 4314 live‐born male control infants without major birth defects, with estimated dates of delivery from 1997 to 2007. Exposure was reported use of prescription or over‐the‐counter medications or herbal products, from 1 month before to 4 months after conception. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression, adjusting for maternal age, race/ethnicity, education, pre‐pregnancy body mass index, previous live births, maternal subfertility, study site, and year. Results We assessed 64 medication and 24 herbal components. Maternal uses of most components were not associated with an increased risk of hypospadias. A new associations was observed for venlafaxine (aOR 2.4; 95%CI 1.0, 6.0) (Correction made here after initial online publication.). The previously reported association for clomiphene citrate was confirmed (aOR 1.9; 95%CI 1.2, 3.0). Numbers were relatively small for exposure to other specific patterns of fertility agents, but elevated aORs were observed for the most common of them. Conclusions Overall, findings were reassuring that hypospadias is not associated with most medication components examined in this analysis. New associations will need to be confirmed in other studies. Increased risks for hypospadias associated with various fertility agents raise the possibility of confounding by underlying subfertility. Copyright © 2013 John Wiley & Sons, Ltd. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pharmacoepidemiology and Drug Safety Wiley

Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997–2007

Loading next page...
 
/lp/wiley/maternal-medication-and-herbal-use-and-risk-for-hypospadias-data-from-eQsbDp4dkp

References (53)

Publisher
Wiley
Copyright
Copyright © 2013 John Wiley & Sons, Ltd.
ISSN
1053-8569
eISSN
1099-1557
DOI
10.1002/pds.3448
pmid
23620412
Publisher site
See Article on Publisher Site

Abstract

ABSTRACT Purpose To investigate associations between maternal use of common medications and herbals during early pregnancy and risk for hypospadias in male infants. Methods We used data from the National Birth Defects Prevention Study, a multi‐site, population‐based, case–control study. We analyzed data from 1537 infants with second‐degree or third‐degree isolated hypospadias and 4314 live‐born male control infants without major birth defects, with estimated dates of delivery from 1997 to 2007. Exposure was reported use of prescription or over‐the‐counter medications or herbal products, from 1 month before to 4 months after conception. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression, adjusting for maternal age, race/ethnicity, education, pre‐pregnancy body mass index, previous live births, maternal subfertility, study site, and year. Results We assessed 64 medication and 24 herbal components. Maternal uses of most components were not associated with an increased risk of hypospadias. A new associations was observed for venlafaxine (aOR 2.4; 95%CI 1.0, 6.0) (Correction made here after initial online publication.). The previously reported association for clomiphene citrate was confirmed (aOR 1.9; 95%CI 1.2, 3.0). Numbers were relatively small for exposure to other specific patterns of fertility agents, but elevated aORs were observed for the most common of them. Conclusions Overall, findings were reassuring that hypospadias is not associated with most medication components examined in this analysis. New associations will need to be confirmed in other studies. Increased risks for hypospadias associated with various fertility agents raise the possibility of confounding by underlying subfertility. Copyright © 2013 John Wiley & Sons, Ltd.

Journal

Pharmacoepidemiology and Drug SafetyWiley

Published: Jul 1, 2013

There are no references for this article.